Proton pump inhibitors and risk of severe COVID-19 in older people

• DOI: 10.1093/ageing/afae082
• Publication Date: 2024-04-15T10:49:26Z
• Authors: Baptiste Gramont; Sophie Fayolle; Diva Beltramin; Nisrine Bidat; Julie Boudet; Robin Chaux; Lucile Grange; Mathilde Barrau; Amandine Gagneux-...; Pascal Cathébras; Martin Killian; Elisabeth Botelho...; Thomas Célarier
• Keywords: 2019-20 coronavirus outbreak

Abstract Introduction Severe acute respiratory syndrome coronavirus 2 is a viral infection that can cause systemic disorders and lead to death, particularly in older people. Proton pump inhibitors (PPIs) increase the risk of enteric lung infections. Considering broad use PPIs people, potential role COVID-19 could be dramatic significance. The objective our study was evaluate link between severe Method We performed retrospective cohort study, including all patients aged ≥65, hospitalised for diagnosis COVID-19. Epidemiological, clinical biological data were extracted we an Inverse Probability Treatment Weighing method based on propensity score. Results From March 2020 February 2021, total 834 included, with median age 83 52.8% male. A 410 had prescription, 358 (87.3%) long-term PPIs-users 52 (12.7%) recent PPIs-users. Among PPIs-users, 163 (39.8%) developed versus 113 (26.7%) PPIs-non users (odds ratio (OR) = 1.59 [1.18–2.14]; P < 0.05). Moreover, double dose PPI-users higher developing (OR 3.36 [1.17–9.66]; 0.05) than full 2.15 [1.22–3.76]; half 1.64 [1.13–2.37]; Conclusion Our reports evidence associated increased